Expectations trend
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.53 → $1.49 · observed estimates
BellRing Brands (BRBR)
NYSEConsumer StaplesPackaged FoodsSnapshot 2026-11-04
$9.81-4.01%
Close 2026-11-05 · 1-day change
NYSEConsumer StaplesPackaged FoodsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.53 → 1.49 EPS · FY ending Sep 30, 2028 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 3 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for BRBR yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA of $315-$335 million in FY26 | Management targets Adjusted EBITDA of $315-$335 million in fiscal 2026. | Broken | Adjusted EBITDA falls below $315 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-09-30 · fmp
$1.53 → $1.49 · observed estimates
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a consumer staples growth business with a sector tailwind, but the evidence does not yet show a steady, durable growth pattern. The multi-year view is intact, while recent misses and elevated risk leave the thesis dependent on improving execution.
BRBR is described as cheap versus peers, and the model shows a negative expectations gap, meaning expectations appear subdued relative to its comparison set. Model confidence is low, and the priced-in assessment says current fragility is justified rather than concentrated.
Near term, sales growth remains modest and mixed: third-quarter net sales rose 4% year over year, while adjusted EBITDA fell in the first half and fiscal 2026 guidance was lowered. Management continues to prioritize growth and profitability, but consecutive earnings misses, inventory-related charges, and inflationary pressure keep results fragile.
The main test is whether brand investment, innovation, and multi-channel execution can support faster revenue growth while cost discipline and pricing improve profitability. A guidance cut after the recent raise would further weaken management credibility; a weakening jobs trend could also weigh on the sector, while stronger results and guidance from sector peers would be supportive.
Over the next 1 to 3 years, the thesis rests on modest sales growth turning into more reliable execution and profitability. The sector backdrop helps, but earnings quality and near-term delivery remain the main uncertainties. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in BellRing Brands's published investment case. The stated target is Operational efficiency improves without further negative surprises. |
| Under Pressure |
| Further negative workforce or litigation events materially impact operations |
Workforce realignment triggered officer departure & litigation; Q3 earnings miss June 2026 workforce realignment caused officer departure and litigation; Q3 2026 earnings missed. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth at or above 2% YoY | A primary condition in BellRing Brands's published investment case. The stated target is >=2% YoY. | Improving | YoY revenue growth falls below 2% in FY26 | Revenue growth: 4.18% FY2026-Q3; GAAP. Published target: >=2% YoY. Annual target cannot be compared with a quarterly or TTM observation. Aug 4, 20264.182648 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 3 of 3 supplied quarters. Management reported: “Third Quarter Operating Results Net sales were $570.4 million, an increase of 4.2%, or $22.9 million, compared to the prior year period, driven by 1.7% increase in volume and 2.5% increase in price/mix.” “Highlights: • Third quarter net sales of $570.4 million, up 4% year-over-year • Operating profit of $65.4 million, net earnings of $34.2 million and Adjusted EBITDA* of $78.3 million, each of which included a pre-tax $10 million inventory-related charge • Updated fiscal year 2026 net sales outlook of $2.335-$2.375 billion and Adjusted EBITDA* outlook of $275-$295 million, inclusive of full year pre-tax $28 million unfavorable impact of inventory-related actions *Adjusted EBITDA is a non-GAAP measure.” Delivery assessment Nov 2, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$2.48B → $2.48B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-10-01 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-02 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-03 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-04 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-05 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-06 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-07 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-08 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-09 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-10 | $1.53 | $2,477,959,896 | 3 / 8 |
| 2026-10-11 | $1.53 | $2,484,089,909 | 4 / 9 |
| 2026-10-12 | $1.53 | $2,484,089,909 | 4 / 9 |
| 2026-10-13 | $1.53 | $2,484,089,909 | 4 / 9 |
| 2026-10-14 | $1.53 | $2,484,089,909 | 4 / 9 |
| 2026-10-15 | $1.54 | $2,481,609,047 | 4 / 9 |
| 2026-10-16 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-17 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-18 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-19 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-20 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-21 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-22 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-23 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-24 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-25 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-26 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-27 | $1.51 | $2,478,256,749 | 4 / 9 |
| 2026-10-28 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-10-29 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-10-30 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-10-31 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-11-01 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-11-02 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-11-03 | $1.49 | $2,475,881,749 | 4 / 9 |
| 2026-11-04 | $1.49 | $2,475,881,749 | 4 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 5 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
0 raises · 1 cuts · 0 unchanged · 2 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.